VivoSeq
Other

Acute Chest Syndrome

15

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Acute Chest Syndrome is an emerging landscape with 15 programs across 8 companies. The most active players are AbbVie, Anthera Pharmaceuticals, Jazz Pharmaceuticals. 2 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

77/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 1A

Anthera Pharmaceuticals

1 program

Phase 2Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Roche logo

Roche

1 program

Phase 3H

Hikma Pharmaceuticals LLC

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

15 of 17 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody16%Peptide16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed10 · 71%
Terminated2 · 14%
Recruiting1 · 7%
Withdrawn1 · 7%

Clinical Trials

Trial Activity

14 trials

Tocilizumab for Acute Chest Syndrome
Recruiting·UUniversity of Chicago·Phase 2·NCT05640271·200 enrolled
Preventing Acute Chest Syndrome by Transfusion Feasibility Study
Completed·CCarelon Research·N/A·NCT00951808·237 enrolled
Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT00748423·100 enrolled
Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial
Completed·VVanderbilt University·Phase 1·NCT02187445·36 enrolled
Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
Completed·CChildren's Healthcare of Atlanta·Phase 3·NCT01380197·40 enrolled
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02580773·198 enrolled
A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Completed·UUniversity of Mississippi Medical Center·Phase 1·NCT02697240·4 enrolled
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
Completed·NNew York Medical College·Phase 2·NCT03805581·20 enrolled
Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01089439·21 enrolled
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
Completed·AAnthera Pharmaceuticals·Phase 2·NCT00434473·30 enrolled
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
Completed·UUCSF Benioff Children's Hospital Oakland·Phase 2·NCT00029731·30 enrolled
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
Terminated·—·Phase 2·NCT02098993·7 enrolled
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
Terminated·—·Phase 3·NCT00530270·12 enrolled
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
Withdrawn·UUniversity of Mississippi Medical Center·Phase 1·NCT02630394

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)